Kite’s route to advance T-cell therapy to the market


Event Details


The KG Jebsen Institute for Cancer Immunotherapy cordially invites you to an exciting talk given by Markwin Velders from Kite Pharma.

Welcome to an exciting one hour seminar about Kite’s route to advance T-cell therapy to the market. The meeting will take place in the auditorium of the research building at Radiumhospitalet, Oslo.

Kite Pharma visits Oslo to kick off their collaboration with the group of Johanna Olweus.

About the speaker

Photo: Hans Lebbe / HLP images

Dr. Markwin Velders brings over 25 years research experience in the field of tumor immunology and over 15 years of management experience in Biotechnology companies. He obtained his PhD from Leiden University in 1996. After a post-doc and associate professorship at Loyola University in Chicago, he was involved in several start-up companies and became Chief Scientific Officer at AM-Pharma in 2004. After bringing two compounds from bench to bed at AM-Pharma, Markwin moved to TNO Biosciences as a Business Unit Manager, managing a group of 150 people. Since 2011 he has been independently active as Prime Life Science, assisting various start-up and early life science companies with their strategy, financing, business development and interim management. He has been involved in the start-up of several new ventures, and secured funding for 4 Life Science start-ups.

End of 2013 Markwin became involved with a potential start up from NKI that was incorporated in 2014 and called T-cell Factory (TCF) and he was instrumental in the M&A deal where Kite Pharma Inc. acquired TCF to form Kite Pharma EU B.V. Since March 2015 he is Vice President Operations and Managing Director of Kite Pharma EU B.V. in Amsterdam.

 

Print This Post